Here's why IP Group looks undervalued. Three brokers take a deep dive

Analysts at three brokerages maintain 'buy' ratings after strong full-year results IP Group PLC (LSE:IPO), the London-listed investor that commercialises intellectual property from leading universities, reported a 13% rise in net asset value (NAV) per share to 110.4p for the year ended December 2025, driven by a licensing deal tied to Pfizer's $10 billion acquisition of obesity drug developer Metsera. The company's shares rose 11% on Tuesday to 54.7p.